Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

期刊论文
出版模式：

开放获取
发表日期：

2024年4月4日

查看全文

Tamiko Tamanaha,
Hisashi Makino,
Cheol Son,
Ryo Koezuka,
Mayu Tochiya,
Yoko Omura-Ohata,
Tatsuya Takekawa,
Masaki Matsubara,
Michio Noguchi,
Tsutomu Tomita,
Kyoko Honda-Kohmo,
Miki Matsuo,
Emi Tateishi,
Tetsuya Fukuda,
Yoshihiro Miyamoto,
Satoshi Yasuda,
Kiminori Hosoda

摘要

Introduction

In patients with type 2 diabetes (T2D), treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors has been shown to reduce hospital admission rates for heart failure (HF). However, the multiple mechanisms hypothesized and investigated to explain the cardioprotection of SGLT2 inhibitors are not fully understood.

Objectives

The effect of luseogliflozin on myocardial flow reserve (MFR) in patients with T2D (LUCENT-J) study aims to examine the effects of SGLT2 inhibitors on myocardial perfusion.

Methods

The LUCENT-J study is a prospective, single-center, randomized, two-arm, parallel-group, open-label (i.e., the radiology readers are blinded), active-controlled study. A cohort of 40 patients with T2D with no or stable (with no history of myocardial infarction and with or without previous percutaneous coronary intervention) coronary artery disease will be included. Patients will be randomized in a 1:1 ratio to luseogliflozin or control and treated for 24 weeks. The primary outcome is the change in MFR, as measured by ¹³N-ammonia positron emission tomography/computed tomography, from baseline to 24 weeks after treatment initiation.

Planned Outcomes

The LUCENT-J study will elucidate the mechanisms of cardioprotection by SGLT2 inhibitors in patients with T2D.

Trial Registration

Japan Registry of Clinical Trials (JRCTs051220016).